Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA Biosciences, the biotech has agreed to sell the deals to an investment ...

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Long-Term Pick. In this article, we will summarize ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money, recently ...

We recently compiled a list of the Jim Cramer Discusses These 11 Stocks & Finds Few Reasons To Sell. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck KGaA (MKGAY), the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics (SWTX), Reuters’ Sabrina Valle ...

Behind Winrevair, the most promising clinical-stage program in Merck's pipeline is a cholesterol drug tentatively named MK-0616. The company started a 17,000-patient phase 3 program to test MK ...